Healthcare Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

 


RELEASE DATE
23-Aug-2010
REGION
North America
DELIVERABLE TYPE
Market Research

RESEARCH CODE
9561-00-AC-00-00
SKU
HC00601-NA-MR_04074
Yes
SHARE

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic
Published on: 23-Aug-2010 | SKU: HC00601-NA-MR_04074

Need more details?

$1,500.00

$1,125.00 save 25 %

DownloadLink
Need more details?

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for B•R•A•H•M•S, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.

This week's issue:


Have questions about this research or need deeper insights?
Speak directly with our analytics experts for tailored recommendations.

Recent related Internet of Things - IOT research

26 Sep 2025   |   Global   |   Technology Research

Innovations in Generative AI, FinOps Solution, Edge AI, Deepfake Detection, Travel Management, App Testing, Cellular and Edge IoT

This edition captures developments related to Generative AI, AI-driven SaaS Platform, FinOps Solution, Edge AI, Deepfake Detection, Smart Travel Management, AI-powered App Testing, Cellular IoT Solution, Industrial IoT Edge Solution, Data Labeling.ITCC TOE’s mission is to investigate emerging wirele...

24 Sep 2025   |   Global   |   Market Research

Global Cellular IoT and Low-Power Wide-Area Network (LPWAN) Market, Forecast to 2030

With the emergence of generative AI (GenAI), embedded SIM (eSIM), and satellite networks, the Internet of Things (IoT) space is undergoing a profound transformation. In response to these emerging trends, this study provides an overview of the traditional cellular IoT, massive cellular IoT, and non-l...

19 Sep 2025   |   Global   |   Technology Research

Recent Advances in Biologics, Regenerative Medicine and Radiotherapies

This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across recent developments for intelligent drug discovery solutions, precision oncology and novel biologics. The TOE also comprises innovations across stem cell therapies and radiotherapies.The ...

17 Sep 2025   |   Global   |   Market Research

IoT-Based HVAC Services Enabling Sustainability of Buildings, Global, 2025–2030

This study examines the emerging role of IoT-based HVAC services in promoting sustainability within the building industry. It highlights the role of real-time data, predictive maintenance, and integration with energy, IT, and building systems in enabling services, including maintenance and repair be...

16 Sep 2025   |   Global   |   Frost Radar

Frost Radar™: Pharmaceutical and Biotech Laboratory Information Management Systems, 2025

The laboratory information management systems (LIMS) market is undergoing a rapid transformation as laboratories look to modernize operations, improve compliance, and accelerate decision-making. The pressure to digitize lab workflows and integrate disparate data sources is positioning LIMS as a cent...

 

Purchase includes:
  • Report download
  • Growth Dialog™ with our experts

Growth Dialog™

A tailored session with you where we identify the:
  • Strategic Imperatives
  • Growth Opportunities
  • Best Practices
  • Companies to Action

Impacting your company's future growth potential.

This issue of Vital Signs, released on August 23, 2010, provides a strategic analysis of trends in biomarkers for improved and accelerated sepsis treatment. Additionally, a company spotlight is provided for BRAHMS, a global biotechnology company committed to improving healthcare through the discovery and development of novel and innovative biomarkers for the diagnosis, treatment, and therapeutic management of severe, life-threatening diseases. Reimbursement and regulatory news from the FDA is also provided for the week of July 26, 2010.
More Information
Deliverable Type Market Research
No Index No
Podcast No
Industries Healthcare
WIP Number 9561-00-AC-00-00
Is Prebook No

Vital Signs - Biomarkers for Improved and Accelerated Sepsis Treatment: Enabling Clinicians to Definitively Diagnose the Disease, Identify the Causative Agent, and Determine the Appropriate Type and Dosage of Antibiotic

$1,500.00

Special Price $1,125.00 save 25 %

In stock
SKU
HC00601-NA-MR_04074